Skip to main content

Table 7 Protective efficacy based on mITT by individual study

From: Summary of anti-malarial prophylactic efficacy of tafenoquine from three placebo-controlled studies of residents of malaria-endemic countries

Study Treatment N # of failures Median failure time (wk)a Person-years  Incidence densityb PE 95 % CI lower limit 95 % CI upper limit
30 Placebo 93 30 10.1 13.26 226.2    
Tafenoquine 200-mg weekly 99 2 NA 20.96 9.5 95.8 82.3 99
Mefloquine 250-mg weekly 96 2 NA 17.9 11.2 95.1 79.3 98.8
43 Placebo 60 54 7.0 7.68 703.2    
Tafenoquine 400-mg load only 57 16 NA 11.96 133.7 81 66.8 89.1
Tafenoquine 200-mg weekly 55 7 NA 12.21 57.3 91.8 82.1 96.3
Tafenoquine 400-mg weekly 57 6 NA 13.58 44.2 93.7 85.4 97.3
45 Placebo 94 86 4.6 9.65 891.6    
Tafenoquine 25-mg weekly 93 58 7.7 15.32 378.7 57.5 40.7 69.6
Tafenoquine 50-mg weekly 91 13 NA 20.67 62.9 92.9 87.4 96.1
Tafenoquine 100-mg weekly 94 11 NA 21.99 50 94.4 89.5 97
Tafenoquine 200-mg weekly 91 12 NA 21.27 56.4 93.7 88.4 96.5
Mefloquine 250-mg weekly 46 6 NA 10.77 55.7 93.8 85.7 97.3
  1. CI confidence interval, mITT modified intent-to-treat, N number of subjects, PE protective efficacy
  2. aMedian time for treatment groups with small number of events cannot be estimated due to the sparseness of the data
  3. bIncidence density rate is expressed in terms of number of prophylactic failures per 100 person-years